DGAP-News: co.don AG

CO. DON AG - Chairman of the Executive Board resigns from his position at the end of 2017

Berlin / Teltow, 18.12.2017 - In agreement with the Supervisory Board, Mr. Dirk Hessel has resigned from his position as member and Chairman of the Management Board of CO. DON AG with effect from the end of December 31,2017 in order to take on new professional responsibilities. At the same time, the Supervisory Board agreed with Mr. Hessel to early termination of his contract, which would normally have ended at the end of June 14, 2018. During Mr. Hessel's time as CEO, CO. DON AG reached a significant milestone in its corporate development with the EU-wide approval of its Spherox product. On this basis, the company's Executive Board has defined the development of European markets as a new strategic goal and has begun the product launch in several European countries. The Supervisory Board of CO. DON AG would like to thank Mr. Hessel for the important contributions he has made in this decisive phase of the company's development and wishes him luck and success for his future professional tasks. The other member of the Executive Board, Mr. Ralf Jakobs, will continue to run the company as sole member of the Executive Board after Mr. Hessel's departure.

CO.DON AG develops, produces and markets autologous cell therapies for the minimally invasive repair of cartilage damage in knee joints following traumatic or degenerative defects. The product being marketed is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method has been used for more than 10 years in over 150 clinics to treat more than 11,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007. In July 2017 the company received EU marketing authorization for Spherox. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO).

More information can be found at www.codon.de

Investor Relations and Press Contact:

Matthias Meißner, M.A.
Corporate communications / IR / PR
Tel. +49 (0)30 240352330
Fax +49 (0)30 240352309
Email: ir@codon.de